SLC5A2 and hydrops fetalis: Recent clinical trials, such as the DAPA-HF and DELIVER studies, have demonstrated strong evidence supporting the effectiveness of SGLT2 inhibitors like dapagliflozin in reducing HF hospitalizations and cardiovascular (CV) events, which are major independent outcomes in HF management [6,7].